20-F: Waterdrop Inc. Files 20-F Report for Fiscal Year 2024, Highlights Financial Performance and Regulatory Landscape

Waterdrop Inc.'s 20-F filing summarizes the company's financial results for the fiscal year ended December 31, 2024, and discusses key aspects of its business, including its corporate structure, regulatory environment, and risk factors.

Summary

• Waterdrop Inc., a Cayman Islands holding company, has released its 20-F filing for the fiscal year ended December 31, 2024.
• The company operates primarily through subsidiaries in mainland China and Variable Interest Entities (VIEs) due to regulatory restrictions on foreign investment.
• VIEs contributed significantly to Waterdrop's revenue, accounting for 93.6% in 2022, 88.6% in 2023, and 83.4% in 2024.
• Waterdrop's net operating revenue increased by 5.4% from RMB 2,630.7 million in 2023 to RMB 2,771.8 million (US$379.7 million) in 2024.
• The company reported a net profit of RMB 350.9 million (US$48.1 million) in 2024, compared to RMB 163.7 million in 2023.
• Waterdrop's medical crowdfunding platform has facilitated RMB 67.5 billion in donations from approximately 470 million donors to 3.40 million patients as of December 31, 2024.
• The company faces legal and operational risks associated with doing business in China, including evolving laws and regulations related to offshore offerings, VIE structures, and data privacy.
• Waterdrop has implemented measures to comply with the Holding Foreign Companies Accountable Act (HFCAA) and expects its ADSs to continue trading in the United States.
• The company's auditor is located in mainland China, and the PCAOB has historically been unable to inspect auditors in that region.
• Waterdrop's ability to pay dividends depends on dividends paid by its subsidiaries in mainland China, which are subject to regulatory restrictions and reserve requirements.
• The company has expanded its business operations into overseas markets, including Hong Kong.
• Waterdrop has made investments and allocated resources in the development and application of AI technologies and may face uncertainties with respect to its commercialization and application and the evolving laws and regulations.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting revenue growth and increased profitability. However, it also acknowledges significant risks and challenges, particularly related to the regulatory environment in China, which tempers the overall sentiment.

Positives

• Waterdrop's net operating revenue increased by 5.4% in 2024.
• The company achieved a net profit of RMB 350.9 million (US$48.1 million) in 2024.
• The medical crowdfunding platform continues to be a significant source of social impact, facilitating substantial donations to patients.
• Waterdrop is proactively investing in AI technologies to enhance its services and operational efficiency.
• The company has been designated by the Ministry of Civil Affairs as a government-recognized online personal help-seeking service platform in mainland China.
• The company's board of directors has approved cash dividends totaling US$0.08 per ADS in 2024 and early 2025.

Negatives

• The company operates primarily through VIEs, which are subject to regulatory risks and uncertainties in China.
• Waterdrop's ability to pay dividends depends on its subsidiaries in mainland China, which are subject to regulatory restrictions and reserve requirements.
• The company's auditor is located in mainland China, and the PCAOB has historically been unable to inspect auditors in that region.
• The company faces intense competition in the third-party insurance brokerage and agency industry in China.
• The company faces risks in properly managing the large amount of cash contributed by donors in its crowdfunding platform.

Risks

• Changes in China's economic, political, or social conditions and government policies could have a material adverse effect on Waterdrop's business and operations.
• The PRC government's significant authority in regulating the industries that Waterdrop operates in and its oversight over securities offerings conducted overseas by, and foreign investment in, China-based issuers could significantly limit or completely hinder Waterdrop's ability to offer or continue to offer securities to investors.
• Evolvements of the legal system in mainland China, including the enforcement of rules and regulations in China and the risk that such rules and regulations can change quickly, could result in uncertainties that could have a material adverse change in Waterdrop's operations and the value of its ADSs.
• Waterdrop may rely on dividends and other distributions on equity paid by its subsidiaries in mainland China to fund any cash and financing requirements it may have, and any limitation on the ability of its subsidiaries in mainland China to make payments to it could have a material and adverse effect on its ability to conduct its business.
• The PCAOB had historically been unable to inspect Waterdrop's auditor in relation to their audit work performed for its financial statements and the inability of the PCAOB to conduct inspections of its auditor in the past has deprived Waterdrop's investors with the benefits of such inspections.
• Waterdrop's ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in mainland China. The delisting of the ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.
• Waterdrop faces risks related to natural disasters, health epidemics and other outbreaks, which could significantly disrupt its operations.

Future Outlook

The company plans to further expand user coverage and engagement, penetrate further into the insurance value chain with strategic partners, invest in data analysis and technology infrastructure, and deepen partnerships with medical institutions to build up a health ecosystem.

Management Comments

• The document does not contain direct quotes from management, but it outlines the company's strategies and initiatives for future growth and development.

Industry Context

The document highlights the competitive landscape of the third-party insurance brokerage and agency industry in China, including online and offline players, as well as traditional insurance intermediaries. It also discusses the evolving regulatory environment and its potential impact on the industry.

Comparison to Industry Standards

• The document does not provide a direct comparison to industry standards.
• However, it mentions key competitors such as Ant Group, WeSure, AIX(formerly Fanhua) and Datong, suggesting that these companies are benchmarks in the industry.
• The document also references the global clinical research and development third-party service market, indicating that Waterdrop is competing in a global market.

Legal Proceedings

• The document mentions a past shareholder class action lawsuit that was successfully defended against.

Related Party Transactions

• The company engages in transactions with Tencent Group, including payment processing, marketing services, and cloud technology services.

Stakeholder Impact

• Shareholders: The company's financial performance and dividend policy directly impact shareholder value.
• Employees: The company's ability to attract and retain talent is crucial to its success.
• Customers: The company's ability to provide valuable insurance and healthcare services impacts customer well-being.
• Insurance Carriers: The company's relationships with insurance carriers are crucial to its success.

Next Steps

• The company plans to further expand user coverage and engagement.
• Waterdrop intends to penetrate further into the insurance value chain with strategic partners.
• The company will continue to invest in data analysis and technology infrastructure.
• Waterdrop aims to deepen partnerships with medical institutions to build up a health ecosystem.

Key Dates

Keywords

Waterdrop, insurance, crowdfunding, VIE, China, financial results, regulatory, risk factors, ADS, HFCAA, PCAOB, AI, data privacy